About Elicera Therapeutics AB

Elicera Therapeutics AB is a clinical stage immuno-oncology company developing next generation cell and gene therapies for immune-based cancer treatments.

Elicera Therapeutics in brief

The company develops four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell therapies, in addition to a platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune enhancement of treatments in said fields.

Elicera's lead programs in each respective field:

  1. ELC-100 is an oncolytic virus, also called AdVince, which is undergoing a clinical phase I/II-study, sponsored by Uppsala University, in neuroendocrine tumors.
  2. ELC-301 is a CAR T-cell therapy, developed initially for treatment of B-cell lymphoma.